Literature DB >> 4619059

Prophylactic activity of mefloquine hydrochloride (WR 142490) in drug-resistant malaria.

K H Rieckmann, G M Trenholme, R L Williams, P E Carson, H Frischer, R E Desjardins.   

Abstract

In preliminary studies with mefloquine (WR 142 490) a single dose exerted prolonged suppressive activity against a drug-resistant strain of Plasmodium falciparum. Development of patent parasitaemia was prevented when nonimmune persons were exposed to infected mosquitos 2 weeks after medication, and it was delayed when exposure occurred 3 weeks after drug administration.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4619059      PMCID： PMC2366307     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  8 in total

1.  THE USE OF SN-10,275 IN THE PROPHYLAXIS AND TREATMENT OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN).

Authors:  T N Pullman; L Eichelberger; A S Alving; R Jones; B Craige; C M Whorton
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

2.  A quinoline methanol (WR 30090) for treatment of acute malaria.

Authors:  D C Martin; J D Arnold; D F Clyde; M al-Ibrahim; P E Carson; K H Rieckmann; D Willerson
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

3.  Clinical testing of new antimalarial compounds.

Authors:  C J Canfield; R S Rozman
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

4.  Determination of the drug sensitivity of Plasmodium falciparum.

Authors:  K H Rieckmann
Journal:  JAMA       Date:  1971-08-02       Impact factor: 56.272

5.  Effects of chloroquine, quinine, and cycloguanil upon the maturation of asexual erythrocytic forms of two strains of Plasmodium falciparum in vitro.

Authors:  K H Rieckmann; J V McNamara; H Frischer; T A Stockert; P E Carson; R D Powell
Journal:  Am J Trop Med Hyg       Date:  1968-09       Impact factor: 2.345

6.  Infections with Plasmodium falciparum and Plasmodium vivax in the owl monkey--model systems for basic biological and chemotherapeutic studies.

Authors:  L H Schmidt
Journal:  Trans R Soc Trop Med Hyg       Date:  1973       Impact factor: 2.184

7.  Treatment of falciparum malaria from Vietnam with a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090).

Authors:  C J Canfield; A P Hall; B S MacDonald; D A Neuman; J A Shaw
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

8.  Prophylactic activity of a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090) in human malaria.

Authors:  D F Clyde; V C McCarthy; C C Rebert; R M Miller
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191
  8 in total
  17 in total

1.  Incorporation of an intramolecular hydrogen-bonding motif in the side chain of 4-aminoquinolines enhances activity against drug-resistant P. falciparum.

Authors:  Peter B Madrid; Ally P Liou; Joseph L DeRisi; R Kiplin Guy
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

2.  Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity.

Authors:  Jong Yeon Hwang; Takashi Kawasuji; David J Lowes; Julie A Clark; Michele C Connelly; Fangyi Zhu; W Armand Guiguemde; Martina S Sigal; Emily B Wilson; Joseph L Derisi; R Kiplin Guy
Journal:  J Med Chem       Date:  2011-09-26       Impact factor: 7.446

3.  Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine).

Authors:  L H Schmidt; R Crosby; J Rasco; D Vaughan
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

Review 4.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

5.  Antimalarial activities of the 4-quinolinemethanols WR-184,806 and WR-226,253.

Authors:  L H Schmidt; R Crosby; J Rasco; D Vaughan
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

6.  An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil.

Authors:  J M de Souza; U K Sheth; R M de Oliveira; H Roulet; S D de Souza
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

Review 7.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

8.  Chloroquine resistance in malaria: accessibility of drug receptors to mefloquine.

Authors:  C D Fitch; R L Chan; R Chevli
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

9.  The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects.

Authors:  J Karbwang; D Bunnag; A M Breckenridge; D J Back
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Evaluation of artemisone combinations in Aotus monkeys infected with Plasmodium falciparum.

Authors:  Nicanor Obaldia; Barbara M Kotecka; Michael D Edstein; Richard K Haynes; Burkhard Fugmann; Dennis E Kyle; Karl H Rieckmann
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.